Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). A phase III study

Next Previous
Trial Profile

Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). A phase III study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms HOVON 97 AML

Most Recent Events

  • 13 Jan 2023 According to European Clinical Trials Database registry, this trial has been completed in Belgium.
  • 14 Dec 2021 Results from HOVON97 and QUAZAR AML-001, determining the relative safety profile and health care resource utilization with Oral-AZA vs SC AZA maintenance therapy in pts with AML in first remission after intensive chemotherapy, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 17 Jun 2021 Results of a comparative analysis of relative efficacy of maintenance therapy with oral versus injectable azacitidine in patients with Acute-myeloid-leukaemia in first remission after chemotherapy performed by matching individual patients data from QUAZAR AML-001 study to summary level data from the HOVON97 and QoLESS studies presented at the 26th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top